The Form 4 filing was submitted on October 13, 2026, for a trade made on October 12. Form 4 is an SEC report of changes in an insider's stock ownership. It identifies Neil F. McFarlane as Zevra Therapeutics' president and chief executive officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-12 |
| Date of Latest Transaction | 2026-10-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 20,000 |
| Price | $11.25 |
| Total Transaction Value | $224,948.00 |
| Insider | |
| Ticker Symbol | ZVRA |
| Company | ZEVRA THERAPEUTICS, INC. |
| Insider Name | McFarlane Neil F. |
| Insider Title | President and CEO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 417,225 |
| Position Size Change | 4.57% |
| Filing | |
| Filing Date | 2026-10-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of 20,000 ZVRA shares. The report lists one transaction under SEC code S, which is used to report stock sales.
What was the average price of the transaction?
The average sale price was $11.2474 per share. Rounded to cents, that is $11.25.
How did this transaction affect the insider's holdings?
After selling 20,000 shares, Neil F. McFarlane reported owning 417,225 shares. The shares sold made up 4.57% of the shares he held before the sale.
What's the total transaction value?
The total sale value was $224,948.00. That amount covers all 20,000 shares in the single reported transaction.
Are there any special circumstances around this transaction?
The transaction information identifies a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The reference may apply to the whole filing. The available details do not confirm that it covers this specific sale. Footnote text and plan terms were not provided, so that link cannot be checked. The plan's start date and trading schedule are also unknown.
For research purposes only; not investment advice.